Trial record 2 of 90 for:    cholangiocarcinoma | Open Studies | Exclude Unknown | "Cholangiocarcinoma"

Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma (4CC)

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified May 2015 by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Information provided by (Responsible Party):
Heinz-Josef Klumpen, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Identifier:
First received: March 10, 2015
Last updated: May 27, 2015
Last verified: May 2015

Cholangiocarcinoma, is a malignant gastrointestinal tumor of low incidence with a poor prognosis. Chemotherapy is the most common treatment for advanced disease. On the basis of a phase III clinical study, cisplatin plus gemcitabine is considered standard first-line treatment in advanced cholangiocarcinoma patients, but there is no established second line therapy.

Since fluorouracil and leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) appears to be safe and demonstrated efficacy in clinical studies of advanced pancreatic cancer, colorectal cancer and a phase I study in cholangiocarcinoma, this combination could be an effective second-line treatment for patients with advanced cholangiocarcinoma.

Condition Intervention Phase
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma

Further study details as provided by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA):

Primary Outcome Measures:
  • pilot study: toxicity [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
    number of adverse events in accordance with CTCAEv4.0

  • phase II: the response rate [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • pilot study: the response rate [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • pilot study: time to progression. [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • pilot study: the overall survival [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • pilot study: quality of life [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • phase II: toxicity during the treatment period and 30 days after the treatment. [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
    number of adverse events in accordance with CTCAEv4.0

  • phase II: time to progression. [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • phase II: the overall survival. [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • phase II: quality of life [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: May 2015
Estimated Study Completion Date: January 2017
Estimated Primary Completion Date: January 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Progressive cholangiocarcinoma, second line treatment
Other Name: Second line treatment


Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histological or cytological diagnosis of cholangiocarcinoma.
  • Metastatic disease or irresectable locally advanced cholangiocarcinoma.
  • Measurable disease according RECIST criteria version 1.1.
  • Age from 18 to 75 year.
  • WHO/ECOG performance status 0-2.
  • Patients who received at least 3 cycles of gemcitabine/cisplatin in the first line.
  • Adequate hematological function (WBC > 3.0 x 109/L, platelets > 100 x109/L)
  • Adequate hepatic function (bilirubin ≤ 1.5 x upper normal limit (ULN); ALAT or ASAT <5x ULN in case of liver metastases and < 2.5 x ULN in absence of liver metastases.
  • Adequate renal function (creatinine clearance > 60 ml/min; creatinine <120 µmol/L)
  • Absence of cardiac insufficiency, chest pain (not medically controlled) and myocardial infarction in the 12 months preceding study entry.
  • Signed informed consent.

Exclusion Criteria:

  • Concurrent secondary malignancies or other malignancies within 3 years prior to enter this study with the exception of non-metastatic basal cell or squamous cell skin cancer or carcinoma in situ of the cervix treated by cone-biopsy or resection
  • Presence of cerebral or meningeal metastases
  • Contraindication to any of the substances of the planned treatment.
  • History of chronic diarrhea or colorectal inflammatory conditions, or of unresolved occlusion or sub-occlusion for which symptomatic treatment is being administered
  • Active infection or other serious underlying conditions which may prevent the patient from receiving the planned treatment. For example: prolonged unresolved bacterial cholangitis with destruction of bile duct branches (e.g. after endoprosthesis insertion) or two or more cholangitis in the last 6 months. Patients with other active or uncontrolled severe infection, cirrhosis or chronic active hepatitis will be excluded.
  • Presence of cardiac insufficiency, unstable angina pectoris, symptomatic congestive heart, failure myocardial infarction 6 months prior to randomization, serious uncontrolled cardiac arrhythmia.
  • Inclusion in another investigational clinical trial
  • Women who are pregnant, breast-feeding or not using adequate contraceptive
  • Age younger than 18 or older than 76 years
  • Individuals under correctional supervision or guardianship
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02456714

Contact: H Klümpen, MD, PhD 31 20 566 5955

Sponsors and Collaborators
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Principal Investigator: H.J. Klümpen, MD, PhD Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Study Chair: J. Wilmink, MD, PhD Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
  More Information

No publications provided

Responsible Party: Heinz-Josef Klumpen, Dr., Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Identifier: NCT02456714     History of Changes
Other Study ID Numbers: volgt
Study First Received: March 10, 2015
Last Updated: May 27, 2015
Health Authority: Netherlands: Medical Ethics Review Committee (METC)

Keywords provided by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA):
Phase II study

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial processed this record on November 27, 2015